Feb 27, 2008 - Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced positive top-line results from its U.S. Phase II clinical trial evaluating Microcyn® Technology as a topical antimicrobial treatment for mildly infected diabetic foot ulcers. Microcyn demonstrated a positive clinical response, defined as the clinical cure or improvement of infection, as a monotherapy and in combination with levofloxacin, a systemic antibiotic. The company plans to request an end-of-Phase II meeting with the FDA to discuss Phase II results and define the scope and parameters for advancing the clinical program... Oculus Innovative Sciences' Press Release -
Monday, March 10, 2008
Oculus Innovative Sciences, Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers
Feb 27, 2008 - Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced positive top-line results from its U.S. Phase II clinical trial evaluating Microcyn® Technology as a topical antimicrobial treatment for mildly infected diabetic foot ulcers. Microcyn demonstrated a positive clinical response, defined as the clinical cure or improvement of infection, as a monotherapy and in combination with levofloxacin, a systemic antibiotic. The company plans to request an end-of-Phase II meeting with the FDA to discuss Phase II results and define the scope and parameters for advancing the clinical program... Oculus Innovative Sciences' Press Release -
